These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37439123)

  • 1. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
    Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jiménez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pollio B; Sigaud M; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
    Mathias M; Abashidze M; Abraham A; Belletrutti MJ; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Lambert T; Kavardakova N; Lohade S; Turea V; Wu JKM; Klukowska A
    Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
    Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Nuwiq
    Zozulya N; Kessler CM; Klukowska A; von Depka M; Hampton K; Hay CRM; Jansen M; Bichler J; Knaub S; Rangarajan S
    Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.
    Lissitchkov T; Klukowska A; Pasi J; Kessler CM; Klamroth R; Liesner RJ; Belyanskaya L; Walter O; Knaub S; Bichler J; Jansen M; Oldenburg J
    Ther Adv Hematol; 2019; 10():2040620719858471. PubMed ID: 31263528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, efficacy and safety of Nuwiq
    Liesner RJ; Abashidze M; Aleinikova O; Altisent C; Belletrutti MJ; Borel-Derlon A; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Fouzia NA; Gattens M; Gruel Y; Guillet B; Kavardakova N; El Khorassani M; Klukowska A; Lambert T; Lohade S; Sigaud M; Turea V; Wu JKM; Vdovin V; Pavlova A; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Haemophilia; 2018 Mar; 24(2):211-220. PubMed ID: 28815880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simoctocog alfa (Nuwiq
    Klukowska A; Sidonio RF; Young G; Mancuso ME; Álvarez-Román MT; Bhatnagar N; Jansen M; Knaub S
    Ther Adv Hematol; 2024; 15():20406207241245511. PubMed ID: 38737006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
    Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries.
    Holme PA; Tjønnfjord GE
    Haemophilia; 2019 Jan; 25(1):54-59. PubMed ID: 30394617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
    Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
    Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
    Astermark J; Olsson A; Chelle P; Täckström K; Walger M; Magnusson M; Iorio A
    Haemophilia; 2021 Jul; 27(4):626-633. PubMed ID: 33966319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
    Nagao A; Deguchi A; Nogami K
    Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.
    Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Tueckmantel C; Cabre-Marquez JF; Wang M
    Eur J Haematol; 2023 Jan; 110(1):77-87. PubMed ID: 36192847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.